Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5690960 | COVIS | Pharmaceutical formulation of omeprazole |
Nov, 2014
(9 years ago) | |
US5900424 | COVIS | Omeprazole magnesium salt form |
May, 2016
(8 years ago) | |
US6428810 | COVIS | Pharmaceutical formulation comprising omeprazole |
Nov, 2019
(4 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Pediatric Exclusivity(PED) | Sep 20, 2011 |
Market Authorisation Date: 20 March, 2008
Treatment: Pediatric use ages 1-2 years, gerd and erosive esophagitis
Dosage: FOR SUSPENSION, DELAYED RELEASE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5690960 | ASTRAZENECA | Pharmaceutical formulation of omeprazole |
Nov, 2014
(9 years ago) | |
US5753265 | ASTRAZENECA | Multiple unit pharmaceutical preparation |
Jun, 2015
(8 years ago) | |
US5817338 | ASTRAZENECA | Multiple unit tableted dosage form of omeprazole |
Oct, 2015
(8 years ago) | |
US5900424 | ASTRAZENECA | Omeprazole magnesium salt form |
May, 2016
(8 years ago) | |
US6428810 | ASTRAZENECA | Pharmaceutical formulation comprising omeprazole |
Nov, 2019
(4 years ago) | |
US6403616 | ASTRAZENECA | Chemical process and pharmaceutical formulation |
Nov, 2019
(4 years ago) |
Market Authorisation Date: 20 June, 2003
Treatment: NA
Dosage: TABLET, DELAYED RELEASE;ORAL